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INTRODUCTION
Head and neck cancers account for 2.8% of all  newly discovered 
cancers1.  Metastatic  carcinoma  within  cervical  lymph  nodes  with  an 
unknown primary tumour site accounts for 3% to 5% of all head and neck 
cancers.1  
          The control  of  such regional  metastatic disease constitutes a 
significant  part  of  the  process  of  treating  head  and  neck  cancer.  The 
presence of an enlarged node proven histologically positive for metastasis 
is an ominous findings and as a general rule decreases the 5-year survival 
rate by at least 50%.When nodal involvement becomes multiple extends 
low in neck, no patient gets cured regardless of the treatment given2.When 
the primary site of carcinoma is known, focused therapy to the primary site 
and  cervical  lymphadenopathy  can  be  given.  Without  this  knowledge 
clinicians are obligated to treat the entire pharyngeal axis and larynx to 
cover the possible origins of the metastatic carcinoma. The occult primary 
treatment  regimen  results  in  a  significant  increase  in  morbidity  to  the 
patient.  Proper  understanding  of  the anatomy and detection  of  cervical 
metastatic disease is crucial to this process.
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AIMS OF THE STUDY
1. To  find  age  and  sex  incidence  of  the  malignant  cervical 
lymphadenopathy with an unknown primary.
2. To analyse the histopathological types common in our population.
3. To stage the disease at the time of presentation 
4. To  interpret  the  possible  site  of  primary  based  on  the  nodal 
involvement.
5.   To describe the various investigations used to identify the primary 
site.
6. To discuss the ideal treatment modality for the patients.
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REVIEW OF LITERATURE
ANATOMY OF THE CERVICAL LYMPHATICS  
The lymphatics has three components ; the capillaries, vessels and 
the nodes.
Capillaries
                   Larger than ateriovenous capillaries, the lymphatic capillaries 
are  thin  walled,  with  a  single  layer  of  endothelial  cells.  Lymphatic 
capillaries are found in all tissues; however they are more abundant in the 
upper  respiratory  and  gastrointestinal  tracts.  Pooled  capillaries  drain 
lymphatic fluid into lymphatic vessels.
Vessels
             As in the capillaries the vessels have a single layer of endothelial 
cells surrounded by an inner longitudinal  elastic layer.  This first  muscle 
layer  is surrounded by a circular smooth muscle layer,  which in turn is 
enveloped by an outer connective tissue layer. Lymphatic vessels contain 
many  more  valves  than  the  venous  system,  with  the  lymph  circulation 
entirely  dependant  on  compression  by  surrounding  muscles,  lymphatic 
vessels drain into lymph nodes.
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Nodes 
               These nodes are of variable size. Typically as many as 75 nodes 
are located on each side of the neck. Nodes contain a subcapsular sinus 
below a prominent capsule, into which lymphatic fluid drains. This capsule 
is  often  the  first  site  of  metastatic  growth.  The  fluid  permeates  the 
substance  of  the  node  (composed  of  cortex  and  medulla)  and  exists 
through  the  hilum  to  enter  more  lymphatic  vessels.  These  nodes  are 
located between the superficial cervical and prevertebral fascia and thus 
are  very  amenable  to  surgical  removal.  The  lymphatic  fluid  eventually 
enters  the  venous  system  at  the  junction  of  the  internal  jugular  and 
subclavian veins3.         
            Except for a few retrovisceral nodes and those deep to the 
sternomastoid  muscle  all  become  palpable  when  enlarged. 
Because tumours have no primary lymphatics,  cancer cells  presumably 
gain  access  to  the  lymphatic  system  at  the  periphery  through  clefts 
between lymphatic endothelial cells.
             Lymphatic  vessels  are  continuously  contracting;  actin  like 
filaments  are  observed  in  lymphatic  endothelial  cells.  The  afferent 
lymphatics join a marginal sinus in the cortex of individual lymph nodes. 
When cancer cells lodge in lymph nodes, proliferation first occurs in the 
periphery  and later  in  the  medulla.  From there  anastamosing  channels 
penetrate the body of the node to form hilar efferent channels into which 
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the marginal sinuses drain directly. The efferent channels from a group of 
nodes  form  lymphatic  trunks  that  in  turn  form  collecting  trunks.  The 
collecting  trunks  drain  into  the  venous  system.  According  to  traditional 
view, cancer cells in the lymphatic system can gain access to the blood 
stream only through these terminal collecting trunks at their junctions with 
major blood vessels. 
LYMPHATICOVENOUS COMMUNICATIONS
Many lymphaticovenous communications exist normally in the body. 
Embryonically  lymphatics  originate  from  buds  of  venous  endothelium. 
Substances  of  varying  sizes  have  been  demonstrated  to  pass  from 
lymphatics to veins within lymph nodes.
          Cells that enter lymphatics are transported to lymph nodes in the 
afferent vessels, are deposited in the peripheral subcapsular sinuses of the 
node,  but  subsequent  process  are  variable,  based on  the existence  of 
lymphatcovenous anastamosis.
          Cancer cells may permanently lodge in the lymph nodes, may 
traverse  nodes  taking  egress  by  efferent  lymphatics  or  through 
lymphaticovenous  communications  within  nodes  to  become 
hematogenously disseminated or may completely bypass lymph nodes to 
enter the blood vascular system4.
          Primary hematogenous spread may occur when cells gain access to 
small  blood  vessels  in  the  tumour  stroma;  such  vessels  develop  from 
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existing host vessels, presumably as a response to tumour angiogenesis. 
Blood borne tumour cells may also traverse interstitial spaces, invade the 
lymphatics and then disseminate via lymphatics.
Thus in addition to the classical  route from the afferent  channels 
through the medulla to the efferent channels, cells may bypass the medulla 
by means of the marginal sinus or may enter the blood stream in the node. 
Additionally lymph nodes may be completely bypassed through collateral 
channels, although this route is enhanced by local obstruction to lymphatic 
flow caused by metastases or reactive lymph node hyperplasia, including 
sinus histiocytosis. Tumuor cells can bypass the nearest regional nodes 
and  proceed  to  more  remote  lymph  nodes.  This  phenomenon  of  skip 
metastases is  seen not  infrequently  in  head and neck cancer  patients. 
There  is  apparently  no  orderly  progression  down lymphatic  chains  and 
hence  into  the  blood  vascular  system  when  lymphatic  depots  are 
saturated5.
          The many oppurtunities for lymphaticovenous and interlymphatic 
communication  prevent  any  rigid  discrimination  between hematogenous 
and lymphogenous metastasis anatomically. This two way communication 
may well  account  for  confused patterns of  metastasis  involving the two 
circulatory systems and argues against metastasis being confined to one 
or the other except perhaps in early subclinical cancer.
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          Although such lymphaticovenous communications exist, whether or 
not they are quantitatively significant under normal physiologic conditions 
is  unknown.  It  is  generally  thought  that  these  channels  are  probably 
dormant until  called in for action by imbalance in intravascular pressure 
precipitated by mechanical obstruction.
       Reversal of lymph flow can be easily produced; retrograde flow of 
lymph is enhanced and filtering efficiency of lymph nodes is decreased by 
inflammation,  fibrosis  from  radiation  and  tumour  growth  with  in  them. 
Tumour  emboli  are  able  to  disseminate  through  existing  or  opened 
anastamoses or in newly formed collateral channels.
WHY CARCINOMA FAVOUR LYMPHATIC SPREAD
 An early step in the metastatic process is the detachment of cancer 
cells or cluster of cells from their parent tumours  .Clusters have better 
chance of survival than single cells.
          Single cancer cells tend to enter the blood or lymphatic systems 
equally,  whereas  cell  clumps are  more  restricted  to  entering  the  blood 
vessels than the smaller  lymphatic channels.
          Because of intimacy with their own blood supply, sarcomas have a 
better chance than carcinomas of gaining early access to blood channels 
and with their  comparatively lower thrombogenic activity they have less 
chance of being held up by intravascular thrombosis than carcinoma cells. 
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Sarcomas also preferentially separate as multicelluar units rather than as 
single cells.  This  would  promote their  survival  in  the blood stream and 
would tend to hinder their access to lymphatic systems.
                   Conversely, the greater tendency of carcinomas to release 
single cells would favour early direct lymphatic spread.
ANATOMY OF NECK NODES
The nodal system of the head and neck consists of two groups ,a 
terminal collecting group known as the deep cervical chain and an outlying 
intermediary group arranged into two circles,the ‘outer circle’ and the ‘inner 
circle’.the internal jugular vein which remains surrounded by nodes of the 
terminal  group lies vertically between the outer  and inner circles of  the 
outlying group.6
          All the lymph from the head and neck ultimately reaches the nodes 
of the terminal group either directly from adjacent tissues or indirectly from 
nodes of the outlying group. In turn lymph from the terminal group drains 
into the jugular lymph trunk that joins the thoracic duct on the left, but on 
the right side opens directly into the jugular or the branchiocephalic vein.
Superior deep cervical group
          This group of nodes drain the soft palate, tonsil,  posterior oral 
tongue, base of tongue, pyriform sinus, supraglottic larynx. The important 
node of  this  group is  jugulodigastric  node otherwise known as tonsillar 
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node. It lies just below and behind the angle of mandible. It is enlarged in 
all cases of tonsillar pathology.
Middle deep cervical group
This group drains the supraglottic larynx, lower pyriform sinus and 
post cricoid area.
Inferior deep cervical group
          This drains the thyroid, trachea and cervical oesophagus. The 
important  node  of  this  group  is  juguloomohyoid.  This  lies  in  the 
intermediate  tendon of  omohyoid  and receives  lymph from tongue and 
submental node.
Spinal accessory chain
          Lies along the course of the spinal accessory nerve and receives 
lymph drainage from scalp, nape of neck and from upper retropharngeal 
nodes.
Left scalene node
          This is located at the junction of subclavian with the thoracic duct 
and receives drainage from thoracic duct.  It  is an important node to be 
looked for in cases of infraclavicular primaries.
Supraclavicular nodes
          This receives afferents from spinal accessory chain and they are 
located in the posterior triangle of neck and occasionally may be involved 
in case of infraclavicular primaries.
14
SUPERFICIAL GROUP OF NODES
This is further divided into
a. inner circle of outlying group and
b. outer circle of outlying group of nodes
Outer circle of outlying group
                This forms a collar in the cervical region.
Occipital nodes
This lies in the apex of posterior triangle and receives drainage from 
scalp and sends efferents to deep cervical group.
Post auricular group
        Lies superficially over the mastoid attachment of sternomastoid and 
receives afferents from post  auricular  area,  scalp and drain into upper 
deep cervical group.
Pre auricular nodes
        This lies in front of the tragus and receives drainage from scalp, 
forhead, pinna, temple, eyelid and external auditory meatus and ultimately 
drains into deep cervical group.                               
Parotid and facial nodes
        Lies within the substance of parotid gland and drains the orbit  , 
parotid  and  infratemporal  fossa.  It  sends  in  efferents  to  deep  cervical 
group.
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Buccal nodes
Lies  over  the  buccinator  muscle  near  lower  border  of  mandible. 
Drains cheek, lower eyelid, sends efferents to jugulodigastric node.
Submental nodes
          This is a group of nodes numbering 3-4, lies in the submental 
triangle and over mylohyoid muscle. Receives afferents from median plane 
structures  and  drains  the  chin  and  portion  of  lower  lip,  mid  portion  of 
gingival, floor of mouth, tip of tongue and nasal vestibule. It sends efferents 
to submandibular group.
Submandibular nodes
                          Lies in the submandibular triangle over the submandibulr  
gland itself.  Facial  artery is in close relation with this node.  This  group 
drains the centre of forehead, nose, upper lip, floor of mouth, cheek, gums, 
major part of tongue and paranasal sinuses(frontal, ethmoidal, maxillary).It 
ultimately drains into jugulo digastric and jugulo omohyoid nodes.
INNER GROUP OF OUTLYING NODES
This  nodes lie  in  relation  to  upper  aerodigestive  tract  and  drains 
larynx, trachea and pharynx. All nodes ultimately drain into deep cervical 
group.
Infra hyoid nodes
Lies in relation to throhyoid membrane and drains the hypopharynx.
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Prelaryngeal nodes
          It is situated in the conus elasticus of the larynx and drains the 
larynx and superior part of isthmus of thyroid.
Pretracheal nodes
          Situated anteriorly and in close relation with inferior thyroid veins 
and drains trachea and inferior part of isthmus of thyroid.
Paratracheal nodes
          Flanks trachea and oesophagus on either side of the course of 
recurrent laryngeal nerve and drains trachea and cervical oesophagus.
Retropharyngeal nodes
          Consists of one median and two lateral groups. Receives drainage 
from nasopharynx, auditory tube and adjacent vertebra.
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CLASSIFICATION OF CERVICAL NODE GROUPS
             Spread patterns of cancer from various primary sites in the head 
and neck to the cervical  nodes have been documented in retrospective 
analyses of large group of patients undergoing neck dissections. Since the 
first descriptions of nodal groups, various classification systems have been 
described.
             To address surgical management of early stage neck metastasis 
via  neck  dissection,  various  authours  have  proposed  a  number 
classification schemes. This lack of uniformity and standardization results 
in redundancy, misinterpretation and confusion among clinicians. The most 
widely accepted terminology was originally described by a group of head 
and  neck  surgeons  at  Memorial  Sloan-Kettering  Hospital.  This 
classification uses neck levels and divides each side of the neck into 7 
separate regions7
• Level I is bordered by the body of the mandible, anterior belly of the 
contralateral digastric muscle and anterior and posterior bellies of 
the ipsilateral digastric muscle. Two nodal subgroups are found, the 
submental group (Ia) is found in the submental triangle(anterior belly 
of  digastric  muscle  and  the  hyoid  bone),and  the  submandibular 
group (Ib) is found within  the submandibular triangle (anterior and 
posterior  bellies  of  the  digastric  muscle  and  the  body  of  the 
mandible)
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• Level  II nodes are located around the upper  third  of  the internal 
jugular  vein,  extending  from  the  level  of  the  carotid  bifurcation 
inferiorly to the skull base superiorly. The lateral boundary is formed 
by the posterior border of the strenocleidomastoid muscle.  Medial 
boundary  formed  by  the  stylohyoid  muscle.  Two  subzones  are 
described; nodes located anterior to the spinal accessory nerve are 
part of level IIa and those nodes posterior to the nerve are located in 
level IIb.
• Level III group defines the middle jugular group nodes limited by 
carotid  bifurcation  superiorly  and  the  cricothyroid  membrane 
inferiorly.  The lateral  border  is  formed by the  posterior  border  of 
sternocleidomastoid  muscle.  The medial  margin  is  formed by the 
lateral border of the sternothyroid muscle.
• Level  IV contains  the  lower  jugular  group  and  extends  from the 
omohyoid superiorly to the clavicle inferiorly.  The lateral border is 
formed by the posterior border of sternocleidomastoid muscle. The 
medial border is formed by the lateral border of the sternothyroid.
• Level  V nodes  re  found  in  the  posterior  neck  triangle,  bordered 
anteriorly by the posterior border of the sternocleidomastoid muscle. 
Posteriorly by the anterior border of the trapezius and inferiorly by 
the  clavicle.  Level  V  includes  the  spinal  accessory,  transverse 
cervical and supraclavicular groups.
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• Level  VI nodes  are  located  in  the  anterior  compartment.  These 
nodes surround the middle visceral structures of the neck from the 
level of the hyoid superiorly to the suprasternal notch inferiorly.
• Level  VII nodes  are  the  paratracheal  nodes  inferior  to  the 
suprasternal notch in the upper mediastinum.
PREDICTABLE ROUTES OF NODAL METASTASIS FROM PRIMARIES 
Cancers of the oral cavity have a predictable manner of spread to 
the cervical nodes. Depending on the site of primary certain patterns of 
metastatic involvement are evident.
          Lesions of lip, anterior buccal mucosa, anterior gingival and floor of 
mouth are typically metastatic to submandibular and submental group of 
nodes. Lesions of tongue, posterior gingival and retromolar area involves 
upper  deep  cervical  chain  commonly.  The  submandibular  node  is  the 
commonest  node  to  be  involved  in  carcinomas  of  floor  of  mouth  and 
jugulodigastric is the commonest node involved in cancers of oral tongue.
          The oropharynx consisting of retromolar trigone, anterior fauces, 
tonsil,  soft  plate and base of  tongue drains primarily into juguodigastric 
node.  The  commonest  node  to  be  involved  in  tonsillar  carcinoma was 
jugulodigastric  node.  Cancers  of  soft  palate,  base  of  tongue  and 
oropharyngeal  wall,  because  of  proximity  to  midline  tended  to  involve 
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bilateral  jugulodigastric  and  rarely  bilateral  posterior  triangle  nodes 
(Lindberg et al).
          Tumours  of  the  nasopharnx  most  commonly  metastasise  to 
jugulodigastric  nodes,  bilaterally  and  in  significant  number  of  patients 
posterior triangle is also involved.
          Tumours of the hypopharynx and supraglottic larynx tended to 
metastasise  to  jugulodigastric  nodes  followed  by  mid  and  lower  deep 
cervical chains.
          Tumours of thyroid commonly involved upper or lower deep cervical 
group of nodes depending on site of tumour (upper pole or lower pole).
SEQUENTIAL SPREAD
          Not only is the topograghic location of involved nodes predictable for 
the various anatomic sites, but the sequential spread from one echelon to 
the  other  is  also  predictable.  If  the  first  echelon  of  lymphatics  is  not 
involved,  the  probability  of  involvement  of  the  next  echelon  is  low.  In 
lateralized lesions the probability of contralateral metastasis is low when 
the  ipsilateral  side  of  the  neck  is  clinically  negative.  The  probability 
increases  as  the  extent  of  ipsilateral  metastases  increases.  In  1997 
Molinari and colleagues used a statistical approach to predict the primary 
site based on the number and location of cervical node metastasis. This 
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type of information is very useful in patients who present with an unknown 
primary8.     
 MECHANISM OF LYMPH NODE METASTASIS
             The current hypothesis on the development of malignancies relate 
to  alterations  in  the  normal  mechanisms  of  cellular  proliferation  and 
differentiation  and a  failure  of  cell  death(apoptosis).This  loss  of  growth 
control  of genetic mutations, including the activation of proto-oncogenes 
and/or inactivation of tumour suppressor genes. The resulting phenotypic 
changes  provide  cancer  cells  a  growth  advantage,  including  loss  of 
response  to  normal  growth  controls,  defects  in  response  signals  for 
programmed cell death, resistance to cytotoxicity, and defects in terminal 
differentiation.
               Proposed by Fidler,  the concept of tumour heterogenicity 
suggests that tumours are composed of heterogenous subpopulations of 
cells  differing in  immunogenecity,  invasiveness,  cellular  growth kinetics, 
sensitivity to cytotoxic drugs and ability to metastasize. The local tumour 
environment may favour the development of more aggressive clones in the 
formation  of  metastases.  Although  the  size  of  individual  clones  with 
metastasizing potential in a given tumour is significant, only a very small 
percentage  of  circulating  cells  lead  to  the  development  of  metastatic 
colonies.
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The events  surrounding  the  initiation  of  local  tumour  invasion  by 
epithelial tumours include a loss of cellular adhesion to surrounding tumour 
cells  and  basement  membrane,  invasion  by  malignant  cells  of  the 
subjacent  connective  tissue  by  the  production  of  cellular  enzymes and 
growth  mediators,  cellular  attachment  to  extracellular  membrane 
molecules, neovascularisation and entry or exit from the circulation through 
the attachment to endothelial cell ligands. A repeat of this events occurs at 
the metastatic sites.
          In the case of squamous cell carcinoma of the head and neck, 
malignant  cells  may  progress  from  carcinoma  is  situ  to  microinvasive 
carcinoma,  to  a  deeply  invasive  tumour  with  lymphatic  metastasis. 
Interestingly a head and neck squamous cell carcinoma has the ability to 
manifest at both extremes of histopathological development in the same 
anatomic location. The critical step in the transition from carcinoma in situ 
to microinvasive carcinoma is the destruction of the basement membrane. 
This  destruction  is  accomplished  by  production  of  specific  proteolytic 
molecules  by  the  tumour  cells,  including  matrix  metalloproteinases, 
collagenases and plasminogen activators.
          Angiogenesis is the growth of new capillaries by sprouting from 
established vessels. In normal tissues, self-limiting angiogenesis is a part 
of reproduction and organogenesis in addition to wound repair and healing. 
Conversely,  pathological  angiogenesis  is not  auto regulated, but  results 
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from alterations in growth control mechanisms of disease process. Various 
tumour derived factors (eg,  prostaglandin E2,platlet-derived growth factor, 
transforming  growth  factor-beta,  transforming  growth  factor-alpha,  beta-
fibroblast  growth facto)are still  being investigated for  their  propensity to 
facilitate endothelial cell proliferation.
Recent research looking specifically at the production of cytokines 
regulating immune,  inflammatory and angiogenetic  response in  patients 
with  laryngeal  squamous  cell  cancer  has  revealed  higher  serum 
concentrations  of  the  cytokines  interleukin-6,interleukin-8  and  vascular 
endothelial  growth  factor.  These  agents  may  be  important  in 
proinflammatory and proangiogenetic responses of tumour cells.
          The ability of a tumour to stimulate an angiogenic response should 
directly determine the capability of a tumour to metastasize and ultimately 
kill the host. The literature notes conflicting reports regarding microvessel 
density and nodal metastasis in head and neck squamous cell carcinomas. 
Tumour sites of  varying origins with different vascularisation patterns at 
their primary sites may behave differently. Malignancies of the head and 
neck especially head and neck  squamous cell carcinomas are the result of 
a series of genetic misadventures of squamous epithelial cells leading to 
malignant  transformation.  Variable  genetic  susceptibility,  prolonged 
tobacco and alcohol exposure, viruses and immune suppression all  can 
facilitate these genetic derangements.
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        Tumours  invade  local  connective  tissue  by  the  production  of 
proteinases  and  the  expression  of  surface  markers  that  facilitate 
attachment  to  extracellular  matrix  components.  Tumor  growth  and  size 
being  limited  by  available  nutrients  from  the  surrounding  milieu, 
recruitment of host capillaries leads to the formation of an intramural blood 
supply. Capillary lymphatic invasion by tumour cells allow malignant cell 
dissemination and the establishment of histologically identical tumours at 
distant sites.
Most recently, the expression of vascular endothelial factor-D in a 
mouse tumour model was found to lead to the lymphatic spread of tumour 
cells, tumour angiogenesis and tumour growth.
          The  dissemination  of  tumour  cells  beyond  the  primary  site 
unfortunately remains the most significant factor in prognosis. 
LYMPH NODE AND TUMOUR IMMUNITY
               An early event in the metastatic process is the detachment of 
cancer cells from the parent tumour. Because a tumour has no primary 
lymphatics, cancer cells presumably gain access to the lymphatic system 
through the clefts between the lymphatic endothelial cells at the invasive 
tumour periphery. Once inside the lymphatic channels, cells are carried by 
the  afferent  lymphatics  to  the  regional  nodes  where  they  lodge  and 
proliferate.
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The permeation theory of metastasis introduced by Handley in 1907 
was based on autopsy studies of patients who had died of breast cancer 
and  melanoma.  He  concluded  that  lymphatic  metastasis  originated  by 
continuous  permeation  of  lymphatics  radiating  away  from  the  primary 
tumour  site.  The  permeation  concept  of  lymphatic  metastasis  was  the 
basis for the development of in continuity (en bloc) dissection of nodes with 
primary cancer for head and neck.
Von Recklinghuasen noticed that metastasis could be found in the 
lymph glands when tumour did not involve the intervening lymphatics, and 
the embolic spread of metastasis is now generally accepted.
Handley’s  concept  of  permeation  still  applies  to  some  clinical 
situations;  generally  recurrent  cancer  with  obstruction  of  the  normal 
lymphatic  pathways  leading to  retrograde spread and tumors  in  certain 
sites such as large floor  of  mouth tumours with direct  extension to the 
submandibular  area.  Previously  untreated  primaries  even  if  massive 
seldom involve the neck by direct extension.              
In  the past  it  was believed that  regional  lymph nodes behave as 
traps  against  tumour  cell  dissemination.  This  ‘Filter  Barrier’  hypothesis 
proposes  that  regional  lymph  nodes  serve  as  mechanical  and  biologic 
filters  in  which  phagocytosis  assists  the  more  mechanical  phase  of 
particulate trapping. In various studies, it has been shown that cancer cells 
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can traverse nodes that themselves are free of tumour, implying that the 
node is an ineffective barrier.
Fischer and Fischer reported that  nodes were able to trap 90%of 
infused red blood cells and 40% of carcinoma cells. The nodes did not 
become saturated.  Some studies  have shown that  nodes  are  potential 
barriers  to  infused tumour  cells  for  only  a  limited  time-approximately  3 
weeks. Thereafter the tumour cells are no longer effectively retained.9,10
In a study it has been shown that as the primary tumour increased in 
size  the  number  of  cells  in  the nodes remained constant.  The authors 
concluded that the nodes had a reasonably constant holding capacity and 
that above such a threshold, all other tumour cells passed on into efferent 
channels and the general circulation.11 
Although the role of  regional  lymph nodes as a barrier  to  cancer 
spread and as a possible site of antitumour immune response is putative 
and remains to be established, majority of the workers are of the opinion 
that some sort of dynamic interaction does occur when tumour.
Emboli encounter lymphocytes within the nodes of head and neck 
cancer  patients.  The  regional  nodes  are  felt  to  be  important  for  the 
initiation  of  systemic  immunity  to  cancer  cells,  especially  to  weekly 
antigenic tumours. Patients who do not become positive for nodes at any 
time  are  thought  to  have  immune  competence  that  is  entirely  able  to 
eliminate  disseminated  tumour  cells  in  the  nodes  and  elsewhere 
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throughout  the  body.  Conversely  the  positive  lymph  node  may denote 
either a failure of the above mechanism, or a change in the biologic nature 
of the tumour cells, or that the number of disseminated tumour cells have 
exceeded the capacity of the node for cell destruction.
The existence of an enlarged node does not necessary indicate the 
presence of metastatic spread, especially if the node is soft. In this case it 
may represent no more than a coincidental infection or the mounting of an 
immunological reaction within the node.
          However just as this is true, it has been estimated that a node 
smaller than 1 cm is impalpable and yet may contain 106 – 107  tumour 
cells. The principal problem for the clinician is how to decide whether a 
node which  is  palpably  enlarged is  involved with  metastasis  or  not.  At 
present  such  a  decision  remains  purely  clinical.  Some  authors  have 
recommended that any enlarged palpable node in the drainage area of a 
histologicaly  proven  primary  should  be  considered  as  metastatic  until 
otherwise proved. Lindberg (1972) defined a clinically positive node as one 
which is  greater  than 1cm in  size,  spherical  rather  than a flat  ovoid in 
shape and harder in consistency than a non metastatic node.
          Throughout this study the above criteria of Lindberg was used to 
differentiate a metastatic from a non metastatic node.
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THEORIES FOR THE OCCULT PRIMARY
It  has  been  hypothesized  earlier  that  the  patient  with  malignant 
cervical lymphadenopathy but unknown primary site may in fact have no 
upper aerodigestive tract primary site. Rather the tumor primary developed 
in the neck within squamous cells remaining as remnants of brachial cleft 
cysts. Although this theory is intriguing, little evidence has been presented 
to support it and it has largely fallen out of favour.
          The other theory is that these patients have exhibited spontaneous 
regression  of  the  primary  tumor  site  with  persistence  of  cervical 
metastasis.  Unfortunately  there  is  no  evidence  for  the  spontaneous 
regression of squamous cell carcinoma.
          Current theory is that unknown primary tumours are likely to be, 
primary tumours that  exist in the upper aerodigestive tracts or skin,  but 
subclinical  at  the  time of  presentation.  Thus  unknown primary  tumours 
remain undetected but are presumed to be present. Anecdotal support of 
this  theory  includes  the  identification  of  some  of  the  primary  tumours 
during or after treatment.
HISTOLOGICAL GRADE OF THE TUMOUR AND ITS INFLUENCE
Histologically a squamuos cell carcinoma consists of an  admixture 
of normal squamous cells and atypical anaplastic  squamous cells. The 
more malignant the tumour, the greater is the number of atypical cells .The 
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atypicality expresses itself in terms of variation in the size and shape of 
cells,  hyperplasia  and  hyperchromatasia  of  the  nuclei,  absence  of 
intercellular bridges, atypical mitotic figures, and keratinisation of cells.
Differentiation  in  a  squamous  cell  carcinoma  takes  place  in  the 
direction of keratinisation, and so the degree of keratinisation represents 
the essential  feature in the system of histological grading introduced by 
Broder  (1921).This  grading  system  recognizes  four  grades  of  severity 
according to the proportions of differentiated cells present in the tumour.
• Grade I - more than 75% of the cells are differentiated
• Grade II – between 50% to 75% of the cells are differentiated
• Grade III – between 25% to 50% of the cells are differentiated
• Grade IV – less than 25% of the cells are differentiated.
Alternatively squamous cell carcinoma can be graded as 
1. Well differentiated – tumours with minimal pleomorphism, few mitoses, 
large number of horn pearls and abundant keratinisation.
2. Moderately  differentiated  –  tumours  where  typical  cells  are 
conspicuous, few horn pearls are present and keratinisation is much 
less evident.
3. Poorly  differentiated  –  tumours  with  much  cellular  and  nuclear 
pleomorphism, negligible keratinisation and absence of horn pearls12.
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The  relevance  of  histologic  grade  of  tumour  to  prognosis  is  well 
established .Arthur and Farr (1972) studied the prognostic significance 
of histologic grade in squamous cell     carcinoma of  oral cavity and 
oropharynx  and  demonstrated  a  clear  relationship  between  the 
histologic grade and metastatic nodal disease, stage of the disease and 
cure rate.  They noted a proportionate increase in nodal  involvement 
with  increasing  histologic  grade  of  the  tumour  and  suggested  that 
histologic assessment should play a part in designing the therapeutic 
approach12.Other  authors  have  also  appreciated  the  usefulness  of 
histologic grading as a clue to overall prognosis13.
                     
TNM STAGING
The  current  classification  was  proposed  by  the  American  Joint 
Committee for Cancer Staging and end results reporting in 20021   and is 
being widely adopted.
In  this  classification,  the  recommended  tumour  (T)  designation 
varies from one anatomic region of the head and neck to another, but the 
node (N) and distant metastasis (M) categories is applicable to all of the 
areas of the head and neck. Stage grouping based on the TNM stage is 
also similar throughout the head and neck.
The (N) and the (M) categories as well as the stage grouping, which 
are constant for all the head and neck regions are discussed first.
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N –Classification of all head and neck cancers (AJCC,2002)1
• Nx - nodes cannot be assessed.
• N0 - no clinical positive nodes.
• N1 –  single clinically positive homolateral  node less than 3cms in 
diameter.
• N2 –single clinically positive homolateral node 3-6cms in diameter, or 
multiple  clinically  positive  homolateral  nodes none over  6  cms in 
diameter.
1. N2a –  single  clinically  positive  homolateral  node 
3-6cms in diameter.
2. N2b –  multiple  clinically  positive  homolateral  node 
none over 6cms.
• N3 –massive homolateral nodes any one node more than 6 cms,
            bilateral nodes or contralateral nodes . 
1. N3a –clinically  positive  homolateral  nodes  at  least 
one greater than 6cms in diameter
2. N3b – clinically positive bilateral nodes
3. N3c – only contralateral clinically positive nodes.
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M - Classification of all head and neck cancers (AJCC,2002)
• Mx – metastasis not assessed
• M0 – No known metastasis
• M1 – Distant metastasis present
STAGE GROUPING OF HEAD AND NECK CANCERS (AJCC,2002)
           Stage I –  T1, N0, M0
           Stage II – T2, N0, M0
           Stage III - T3, N0, M0
                            T1,2,3, N1, M0
           Stage IVa – T4, N0,1, M0
                              T1-4, N2, M0  
                     IVb - Any T, N3, M0
         T4b, Any N, M0
 IVc – Any T, Any N, M1 
The T – classification of the oral cavity and oropharyngeal tumour is 
described below (AJCC,2002)
• Tx – No available information on the primary tumour
• T0 – No evidence of primary tumour
• Tis – Carcinoma in situ
• T1 – Tumour 2cms or less in greatest diameter
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• T2 – Tumour 2 – 4 cms in greatest diameter
• T3 – Tumour more than 4 cms in greatest diameter
• T4 –  Tumour  more  than  4  cms  with  invasion  into  contiguous 
structures such as floor of mouth,   skin, muscles and bone.
• T4a – Tumour involving cortical bone, deep tongue musculature, 
maxillary sinus, skin of face
• T4b –  Tumour  involving maxillary plates,  pterygoid plates,  skull 
base, encases the internal carotid artery7.
RISK FACTORS FOR HEAD NECK CANCER
It has been estimated that the use of tobacco and alcohol can account 
for up to 80 percent of cases of head and neck squamous cell carcinoma. 
Both  act  throughout  the  aerodigestive  tract,  contributing  to  the  field 
cancerisation  effect,  and  both  can  induce  genetic  alterations,  such  as 
mutations in the p53 tumour suppessor gene.  Other factors which may 
play a role include viral infection, oocupational exposure, radiation, dietary 
factors and genetic susceptibility.
• Tobacco-there is an increased risk of head and neck squamous cell 
carcinoma  from  a  5-to-25  fold,  in  heavy  smokers  compared  to 
nonsmokers14.The relative  risk in  current  tobacco users  is  6.5.the 
relative risk increased with the duration of  smoking and gradually 
declined  after  smoking  cessation  with  no  excess  risk  at  20 
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years15.The age at onset of smoking (below 18 years of age) and 
duration of smoking (over 35 years) were high risk factors. Passive 
smoke  exposure  also  may  e  a  contributing  factor.  One  report 
evaluated patients  with  head and neck  squamous cell  carcinoma 
who  did  not  use  tobacco,  with  rare  exceptions,  did  not  abuse 
alcohol. These patients had a significantly higher risk of exposure to 
environmental tobacco smoke in both the workplace and home than 
a  control  population  without  cancer.  This  relationship  primarily 
occurred in women and those with tongue cancer.16
Epidemiologic studies have suggested that cigar smoking is associated 
with an increased incidence of head and neck squamous cell carcinoma17 
and smokeless tobacco with an increased risk of cancer of the tongue, oral 
cavity  and  pharynx.18  Marijuana use  may modestly  increase the  risk  of 
cancer, an effect that is magnified by cigarette smoking.19 
• Alcohol –although  it  is  often  difficult  to  separate  the  effects  of 
smoking and alcohol, studies have consistently shown that alcohol 
consumption  increases  risk  of  cancer  in  the  upper  aerodigestive 
tract.20  The relative risk of  developing cancer appears to be dose 
dependant, ranging from 5.5(alcohol intake greater than 50g/day) to 
33.8(alcohol intake greater than 120g/day) .Drinking liquor may be 
associated  with  greater  risk  than  drinking  only  wine21.  Moderate 
alcohol  intake (10 to  19g/day)  has no effect  among nonsmokers. 
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The combined effect of alcohol and smoking is multiplicative, with 
the risk of developing Head and Neck cancer being as much as 200 
times greater for heavy smokers and drinkers22.
• Epstein-Barr virus-The strongest association between a virus and 
head  and  neck  cancer  is  that  of  Epstein-Barr  virus  and 
nasopharyngeal carcinoma. EBV is the causative agent for oral hairy 
leukoplakia.
• Human papilloma virus- HPV type-16 has been detected in 8 to 36 
% of head and neck cancer23.It may contribute both by direct effects 
on proliferation and by increasing mutational frequency in the host 
cells. The prevalence of HPV infection appears to be site specific, 
and  is  highest  in  invasive  tumours  of  the  oropharynx  and  oral 
cavity24.The presence of HPV appears to confer a better prognosis.
• Occupational  exposure –  These  include  asbestos,  pesticides, 
polycyclic  aromatic  hydrocarbons,  textile  workers,  wood  workers, 
manufacturers  of  mustard  gas,  plastic  and  rubber  products, 
naphthalene refineries, ethanol, sulfuric acid mist, leather and paint 
workers, automobile mechanics, construction workers(cement),metal 
workers  and  bartenders(passive  smoking).Formaldehyde  was 
classified as a carcinogen in 2004 because of its association with 
nasopharyngeal carcinoma and possibly cancers of the nasal cavity 
and paranasal sinuses.
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• Radiation – Prior radiation for either malignant or benign disease 
has been linked to head and neck cancer.
• Diet  – Risk of nasopharyngeal carcinoma is increased in frequent 
consumers of preserved meats which contain high levels of added 
nitrites25.Increased risk of head and neck squamous cell carcinoma 
has also been associated with more frequent intake of eggs and red 
meat and a low carotenoid intake26.
• Genetic factors – First degree relatives and siblings of patients with 
head and neck squamous cell carcinoma are more likely to develop 
upper aerodigestive tract cancer than controls27.
• Others – Poor oral hygiene has been linked with carcinoma of oral 
cavity28. Lip cancer is seen in renal transplant recipient.
DIAGNOSTIC EVALUATION
A complete detailed history of the present and past illness with a 
thorough physical examination is a mandatory to the workup of the patient. 
          Laboratory studies are not typically used in the workup of a patient 
but  are  used  to  evaluate  a  patient’s  anaesthetic  risk  and  to  provide 
baseline laboratory data.
Serology of Ebstein-Barr virus has been shown to correlate with the 
presence of nasopharyngeal carcinoma29.
Chest radiograph                             
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          Chest radiograph are taken for all patients. If any suspicious lesion 
found in chest radiograph then CT scan is indicated. If a lung neoplasm is 
found then it is evaluated separately.
CT scan
          The neck CT scan is important in the search for an occult primary 
site and also to evaluate the extent of nodal disease, to check for obvious 
extra  capsular  spread  and  soft  tissue  involvement  and  examine  for 
suspicious nodes in the contralateral neck. Contrast enhanced CT from the 
base of  the skull  to  the level  of  the thoracic  inlet  is  indicated.  CT can 
identify  tumours  of  the  head  and  neck  based  upon  either  anatomic 
distortion or specific  tumour enhancement.  In  general  tumours enhance 
more  than  any  normal  head  and  neck  structures  except  mucosa, 
extraocular muscles, and blood vessels  30. A radiologically heterogenous 
appearance  or  the  presence  of  central  low  attenuation  may  indicate 
pathologic lymphadenopathy, even in small lymph nodes.
 MRI  scan        
          MRI  has multiplanar capabilities, it provides superior soft tissue 
contrast  and  it  can  identify  early  evidence  of  dural  involvement  or 
perineural invasion 31. It is therefore useful for assessment of local spread 
of nasopharyngeal carcinoma and sinonasal carcinoma. MR Angiography 
can generate images of large arteries and veins noninvasively without the 
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use of IV contrast. This is reserved for cases where tumour is thought to 
encase a major vessel.           
PET scan
Usefulness  of  PET  scanning  is  still  evolving.  Potential  clinical 
applications for the PET scanning include improved pretreatment staging, 
identification of an occult  primary site,  estimation of treatment response 
and differentiation of early recurrence from scar tissue32 . Many incorporate 
this imaging modality in their diagnostic evaluation for an occult primary 
tumour.  Tumour  cells  have a higher metabolic  rate than normal  tissue; 
head and neck neoplasms have an increased glycolytic rate. Thus head 
and neck neoplasms are good candidates for metabolic imaging and can 
be traced using a glucose analog, 2-[fluorine-18]fluoro-2deoxy-D-glucose.
(FDG).           
          FDG uptake reflects cellular metabolism and cellular processes such 
as  infection,  neoplasm  or  inflammation.  They  are  characterized  by 
increased  metabolic  activity  and  consequent  accumulation  of  the  FDG 
tracer. This accumulation which appears as hot spots on PET imaging may 
help to localise an unknown primary tumour.
The Danish study demonstrated that FDG PET detected a primary 
tumour  in  24%  of  patients  with  metastatic  cervical  adenopathy  and 
otherwise negative clinical and radiological evaluation.
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          The key limitation of PET has been the size of tumour it can detect. 
Commonly  available  PET  scanners  may  have  a  resolution  of 
approximately 1cm.That is they will  inconsistently detect  lesions smaller 
than this size. New PET have resolution of 5mm.An additional limitation of 
PET scanning has been the anatomically nonspecific image produced by 
these  scanners.  Hot  spots  appear  as  general  regions  without  good 
borders. So whereas it may be possible to state for eg; that left side of the 
base of the tongue appears ‘hot’, any additional information regarding the 
size or localization would be inaccurate.
          Newer scanners that supplement PET with CT fusion techniques are 
becoming available. These machines can overlay the images so that the 
hot areas are visible as coloured halos over the CT scan image, greatly 
facilitating the accuracy and localization of the PET technology. 
          Panendoscopy of the upper aerodigestive tract with biopsy samples 
obtained from suspicious areas should be done.
          Mucosal  biopsies of nasopharynx,fossa of rosenmuller, tonsils, 
pyriform sinus,   hypopharynx,  vallecula,  postcricoid  region and base of 
tongue should be done routinely for all patients with unknown primary.
             Previous studies have suggested that the most common sites of 
primary  tumour  detected  on  panendoscopy  were  the  nasopharynx  and 
hypopharynx. In a recent University of  Florida study,  the most common 
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sites of primary cancer detected seen now to have shifted to include the 
tonsillar  fossa or the base of the tongue33 .
             Because the tonsil remains a common site of primary tumour , 
most clinicians advocate tonsillectomy in addition to directed biopsies in 
the workup of an unknown primary tumour. Questions regarding whether 
random  tonsil  biopsies  or  tonsillectomy  should  be  performed  in  the 
evaluation  of  an  unknown primary  site  and whether  such  tonsillectomy 
should be ipsilateral or bilateral tonsillectomy continue to be controversial.
             In  a 1998 study at  john Hopkins hospital  McQuone et  al 
demonstrated  that  the  detection  rate  of  occult  tonsillar  carcinoma  is 
increased by performing tonsillectomy rather  than focal  tonsillar  biopsy. 
Although  only  13%  of  tonsillar  biopsy  specimens  were  positive  for 
squamous  cell  carcinoma,  39%  of  the  patients  undergoing  bilateral 
tonsillectomy  for  workup  of  unknown  primary  site  was  found  to  have 
squamous cell carcinoma within tonsil. Furthermore one patient was found 
to  have  squamous  cell  carcinoma  in  both  tonsils,  strengthening  the 
argument  for  bilateral  tonsillectomy.  Bilateral  tonsillectomy  does  not 
significantly  increases  the  morbidity  associated  with  unilateral 
tonsillectomy and eliminates the asymmetry that can confound follow up 
examination after a unilateral procedure 34.
TREATMENT
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Several  different  treatment  strategies  are  available  for  the 
management  of  the  true  unknown  primary  site  and  squamous  cell 
carcinoma metastatic to the neck. Whether radiation therapy is sufficient 
treatment for control of neck disease and whether potential primary sites 
should  be  irradiated  or  simply  followed  are  controversial.  Additional 
controversy focuses on whether radiation should be offered to patients pre- 
or  postoperatively.  Finally,  questions  have  surfaced  about  whether  the 
contralateral neck needs to be treated. Which treatment strategy provides 
best outcome remains a subject of debate in the literature.
          In discussing treatment strategies, it is important first to have an 
understanding of prognostic factors. In all large series, lymph nodal stage 
has correlated with outcome. Supraclavicular lymph node metastases are 
more likely to be associated with disease below the clavicles, and hence, 
are associated with poorer survival.  Histologic extracapsular spread has 
been noted to affect survival adversely in most large series as well.  As 
might be expected, more primary sites were identified in patients treated 
with surgery than in patients treated with radiation.   Although treatment 
protocols may vary by institution and clinical bias, there is consensus that 
advanced  nodal  disease  and  extracapsular  spread  necessitate  more 
aggressive therapy35.
               For a few patients presenting with N1 or N2a disease, single 
modality  therapy  is  a  reasonable  approach.  Acceptable  courses  of 
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treatment  include  neck  dissection  alone,  radiation  alone,  and  neck 
dissection plus radiation if extracapsular spread is noted on histopathologic 
analysis.  A  1998 review from M.D.Anderson  recommends  that  patients 
with N1 or small mobile N2a disease be treated with neck dissection alone 
and  that  postoperative  radiation  therapy  be  reserved  for  cases  of 
extracapsular spread, multiple nodes or connective tissue invasion36.  The 
5-year disease free survival rates were 85% in patients with a solitary node 
and 58% for patients with multiple nodes. Similarly, in patients who have 
undergone an excisional biopsy of a solitary node, the neck may be treated 
with  radiation alone with  a  95% likelihood of  neck control.  Thus single 
modality treatment in patients with N1 or N2a disease is reasonable .For 
patients  with  disease beyond N1 or  N2a combined modality  therapy is 
recommended.
               Patients with more advanced disease, in contrast are triaged into 
an  arm  of  treatment  that  includes  both  surgery  and  radiotherapy.  The 
timing  of  radiotherapy  is  also  a  source  of  controversy.  Proponents  of 
preoperative radiation therapy argue that surgical complications delay the 
initiation  of  radiation  therapy,  target  tissues  are  theoretically  better 
oxygenated in the preoperative state, and radioresistant primary tumours 
may become evident  over  the  course  of  radiation  therapy  and  can  be 
removed  with  one  definitive  surgical  procedure  if  radiation  therapy  is 
implemented before the planned neck dissection34.
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Proponents  of  postoperative  radiation  therapy  argue  that  a  neck 
dissection  before  radiotherapy  allows  improved  delineation  of  disease 
extent  and  better  staging  through  pathologic  evaluation  of  the  neck 
dissection specimen37. Although adjuvant chemotherapy has shown mixed 
results, it  is often recommended in cases of inoperable disease or with 
distant metastases. There is some evidence that concurrent chemotherapy 
and radiotherapy in the postoperative setting improve locoregional control 
rates.
          The decision to include suspected primary sites in the radiation field 
also remains controversial. Certainly the challenge facing the clinicians is 
deciding  how to  maximize  the  chance  of  survival  while  minimizing  the 
treatment morbidity. Review of the literature reveals a trend toward treating 
both the ipsilateral and contralateral necks as well as potential mucosal 
primary  sites.  Certainly  many  of  the  primary  sites  (base  of  tongue, 
nasopharynx,  supraglottis)  are  known for  their  bilateral  nodal  drainage. 
Tong et al38 point out that treatment limited to the involved side of the neck 
alone may compromise further radiation therapy should a primary mucosal 
site emerge. For this reason, bilateral radiation to the neck and mucosal 
sites is recommended.
Debate continues to center around which portals should be included 
in the radiation therapy. The consensus seems to be that the oral cavity 
and  a  laryngeal  strip  can  be  excluded,  but  the  base  of  the  tongue, 
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hypopharynx, and supraglottic sites should be included39. The decision to 
include the nasopharynx should be based on whether metastases are high 
and posterior and whether demographic factors suggest that the patient is 
at high risk for a nasopharyngeal primary site. Sparing the oral cavity and 
of  an  anterior  strip  approximating  the  anterior  true  vocal  cords  may 
significantly decrease the morbidity of the mucosal irradiation.
          Regarding ipsilateral versus bilateral treatment of the sides of the 
neck,  Carlson  et  al40 demonstrated  that  the  rates  of  local  control  for 
ipsilateral and bilateral neck irradiation were 53% and 90% respectively. 
Reddy et al41 also reported a series comparing ipsilateral radiotherapy with 
radiation  delivered  to  both  sides  of  the  neck  and  sites  of  mucosal 
primaries. Significantly better neck control was demonstrated in the group 
receiving radiation to both sides of the neck and mucosal sites.
          Finally,  recent  discussion has focused on the extent  of  neck 
dissection indicated in the patient with a cervical metastasis and unknown 
primary lesion. A growing body of evidence suggest that a selective neck 
dissection  including  the  involved  level  and  contiguous  levels  with 
appropriate sacrifice of the involved structures is reasonable. Appropriate 
use of selective neck dissection can minimize the postoperative morbidity 
associated with modified and radical neck dissection without compromising 
neck control and survival42.
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Even with advances in treatment protocols, the overall survival for 
squamous cell carcinoma metastatic to a cervical node with an unknown 
primary site remains approximately 50%.The 2-,5-  and 10 year disease 
specific  survival  rates  have  been  reported  to  be  82%,74%  and  68% 
respectively. Nodal stage has been shown to be significantly associated 
with disease specific survival.
CHEMOTHERAPY
          The role of chemotherapy in head and neck cancer is expanding and 
its utility varies with the stage of the disease. For patients with metastatic 
or incurable locoregional disease chemotherapy is palliative. In contrast for 
patients  with  potentially  curable  locoregional  head  and  neck  cancer, 
chemotherapy is an integral part of multimodality approach. In such cases 
chemotherapy may be administered as induction therapy, concomitant with 
radiotherapy or with a combined approach.
Single agent chemotherapy
          Several cytotoxic chemotherapy drugs have significant activity in 
advanced head and neck cancer when administered as a single agent. 
Direct  comparisons of  efficacy are limited by the paucity of  randomized 
trials,  and  this  complicates  the  establishment  of  recommendations  for 
standard of cure. Although most patients will be treated with combination 
chemotherapy, occasionally single agents may be used for palliation.
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The  choice  of  agents  depends  in  part  upon  the  patient’s  clinical 
status  and  the  ability  to  tolerate  drug-specific  side  effects.  Acceptable 
drugs  include  paclitaxel,  docetaxel,  methotrexate,  cisplatin,  carboplatin, 
ifosfamide and 5-Fluorouracil.
In advanced squamous cell head and neck cancer, the taxanes have 
emerged as perhaps the most active of all single agents.
General principles of combination chemotherapy
          Many combination chemotherapy regimens have been studied for 
the treatment of advanced head and neck cancer. Prior to mid 1980s, the 
most aggressive regimens included methotrexate and generally consisted 
of  combinations of  two or  four  drugs,  often methotrexate plus cisplatin, 
bleomycin,  5-FU  or  vincristine.   These  regimens  have  been  largely 
replaced by three categories of drug combination:
• The combination of a platinum analog (cisplatin or carboplatin) and 
5-FU.
• The combination of a platinum analog and a taxane (paclitaxel or 
docetaxel ).
• The combination of a taxane, a platinum analog and 5-FU with or 
without leucovorin.
Recommendations for combination chemotherapy for advanced head and 
neck cancer.
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            For metastatic or recurrent disease, any of the several regimens 
may be used. Since none has been proven yet to prolong survival, care 
must  be  exercised  to  avoid  major  acute  or  chronic  toxicities  and 
consideration should be given to single agent therapy.
           For  patients  with  good  performance  status,  appropriate 
combinations include cisplatin or carboplatin plus 5-FU, or platinum analog 
plus a taxane.
NEW THERAPIES UNDER INVESTIGATION
Monoclonal antibodies
Cetuximab- The majority of  head and neck cancers over express 
endothelial  growth factor,  making them a good target for cetuximab, an 
anti-EGFR monoclonal antibody that inhibits receptor activity by blocking 
the ligand binding site. In addition to being investigated as a single agent 
and in combination with cytotoxic chemotherapy, cetuximab is also under 
study as a radiosensitiser.
          Other potential agents that block the activation of EGFR are the 
tyrosine inhibitors such as geftinib and erlotinib.
Gene therapy
Gene therapy utilize a vector to deliver genetic material to a cell in 
an attempt to alter its biology via expression of the delivered gene. The 
majority of effort has been aimed at modification of p53.The p53 gene is 
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inactivated  in  approximately  one half  of  squamous cell  head and neck 
cancers.  
ONYX-015 – It is an adenovirus containing a deleted E1B 55-kDa 
gene, which actively replicates in, and lyses p53-deficient cells.
RPR/INGN  201  –  It  utilizes  a  replication  deficient  adenovirus  to 
deliver a cytomegalovirus promoter and a wild type p53 gene.
Cisplatin/epinephrine injectable gel – for patients with refractory or 
multiply  recurrent  local  tumour  involvement,  a  novel  strategy  is  direct 
application of cisplatin into the tumour itself. 
RADIOTHERAPY
          Radiation may be given as  a  once daily  treatment  or  hyper 
fractionated (twice daily).It may be continuous (five days per week without 
interruption ) or given in a split course (every other week or three weeks on 
with a one or two weeks break followed by three more weeks of treatment).
   
NECK DISSECTION
 Introduction
Cancers  in  the  head  and  neck  region  commonly  metastasize  to 
cervical  lymph  nodes.  The  term  neck  dissection  refers  to  a  surgical 
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procedure in which the fibro fatty contents of the neck are removed for the 
treatment  of  cervical  lymphatic  metastases.  Neck  dissection  is  most 
commonly  employed  in  the  management  of  cancers  of  the  upper 
aerodigestive tract. It is also used for malignancies of the skin of the head 
and neck area, the thyroid, and the salivary glands.
Radical neck dissection has been the standard surgical procedure 
for treatment of  metastatic  neck cancer since its description by Crile in 
1906. Until only a couple of decades ago, it was widely used as an elective 
procedure  for  occult  neck  disease  and  as  a  therapeutic  procedure  for 
clinically manifest  nodal  metastases. However,  in the last 2 decades, a 
shift  toward  the  use  of  more  conservative  surgical  procedures  has 
occurred, arising from the realization that many non lymphatic structures in 
the neck,  as  well  as  certain  lymph node groups,  may be preserved in 
certain situations without compromising disease control.
Experimental  studies of  lymphatic drainage and clinical  studies of 
nodal  distribution  have  enabled  reliable  prediction  of  the  lymph  node 
groups  most  likely  to  be  involved  with  metastatic  disease  for  different 
locations of the primary tumor. Importantly, establishing which lymph node 
groups carry negligible risk of involvement and may be safely preserved is 
also possible. As a result, a great variety of surgical procedures have now 
been described for use in varying clinical situations.
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The  current  classification  of  neck  dissections  by  the  American 
Academy of  Otolaryngology /  Head and Neck Surgery is  based on the 
following governing principles:
♦ Radical neck dissection is the standard basic procedure for cervical 
lymphadenectomy, and all other procedures represent one or more 
modifications of this procedure.
♦ When  modification  of  the  radical  neck  dissection  involves 
preservation of one or more non lymphatic structures, the procedure 
is termed a modified radical neck dissection.
♦ When the modification involves one or more lymph node groups that 
are routinely removed in the radical neck dissection, the procedure 
is termed a selective neck dissection.
♦ When the modification involves removal  of  additional  lymph node 
groups  or  non  lymphatic  structures  relative  to  the  radical  neck 
dissection,  the  procedure  is  termed  an  extended  radical  neck 
dissection
This classification was developed by the Committee for Head and Neck 
Surgery and oncology, American Academy of Otolaryngology – Head and 
Neck  surgery,  Courtesy  of  the Archives  of  Otolaryngology –  Head and 
Neck Surgery.
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♦ Radical neck dissection
♦ Modified radical neck dissection
♦ Selective neck dissection
o Supraomohyoid type
o Lateral type
o Posterolateral type
o Anterior compartment type
♦ Extended radical neck dissection.
Radical neck dissection
Originally described by Crile in 1906, this procedure is an en bloc 
clearance of all fibro fatty tissue from one side of the neck, including the 
lymph nodes from level I through V, lymph nodes43. Surrounding the tail of 
the parotid gland, the spinal accessory nerve, the internal jugular vein, and 
the sternocleidomastoid  muscle.  It  does not  include the removal  of  the 
postauricular,  suboccipital,  perifacial  buccinator,  retropharyngeal  and 
central compartment nodes.
Previously used for neck disease of any stage, from microscopic to 
bulky  nodal  disease,  this  procedure  now finds  its  application  limited  to 
patients with advanced neck disease or with gross extracapsular spread to 
52
the spinal accessory nerve, sternomastoid muscle and the internal jugular 
vein.
Modified radical neck dissection
This operation involves the removal of the same lymph node groups as the 
radical neck dissection (levels I through V) but requires preservation of 1 or 
more of the 3 non lymphatic structures; the spinal accessory nerve, the 
internal jugular vein, and the sternomastoid muscle.
Modified neck dissection is indicated in cases with clinically palpable 
metastatic  neck  disease.  Conversion  to  the  radical  neck  dissection 
becomes  necessary  when  gross  involvement  of  the  nerve,  vein  and 
muscle is present, although the involvement of all 3 is unusual, except in 
very advanced (N3) disease.
Comprehensive neck dissection is a term that frequently appears in 
the  literature.  This  refers  to  any  type  of  neck  dissection  that  involves 
removal  of  lymph  nodes  from  levels  I  through  V  and  corresponds, 
therefore, to radical and modified radical neck dissections according to the 
Academy’s classification.
Selective neck Dissection
This term refers to a type of neck dissection in which certain lymph 
node groups in the neck are preserved while others are removed. Included 
in  this  category  are  supraomohyoid  neck  dissection,  lateral  neck 
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dissection, anterior compartment neck dissection, and posterolateral neck 
dissection.
Supraomohyoid neck dissection
Selective  removal  of  the  level  I,  II  and  III  lymph nodes  is  called 
supraomohyoid neck dissection.  The operation includes the resection of 
soft tissue in the submental triangle, along with the submandibular triangle 
contents, including the submandibular gland and the fibrofatty tissue along 
the internal  jugular  vein  in  the  upper  2  levels.  The dissection contents 
include the fascia covering the medial aspect of the sternomastoid muscle; 
the muscle itself is retracted laterally and preserved. These neck contents 
are peeled off from the internal jugular vein and from around the accessory 
nerve, sparing these structures.
Supraomohyoid  neck  dissection  is  indicated  for  the  prophylactic 
treatment of occult neck disease in cancers known to metastasize to this 
group of nodes, i.e cancers of the oral cavity. Application of this type of the 
neck dissection to treat clinically positive nodes remains controversial. If 
this  operation  is  performed  for  N+  disease,  including  level  Ic  in  the 
dissection may be prudent.
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Lateral Neck dissection
Selective removal of the soft tissues containing the level, II, III and 
IV  lymph  nodes  along  the  internal  jugular  vein  is  called  lateral  or 
anterolateral neck dissection. The spinal accessory nerve, sternomastoid 
muscle, and internal jugular vein are spared in this operation.
This operation is commonly performed for the prophylactic treatment 
of  occult  disease  in  patients  with  primary  cancers  in  the  oropharynx, 
hypopharynx,  or  larynx.  Its  application  in  the  N+ situation is  still  under 
investigation.
Both the supraomohyoid and the lateral neck dissections may need 
to  be  performed  on  both  sides  in  patients  whose  primary  tumors  are 
located close to or across the midline. Cancers of the central tongue, floor 
of  the mouth,  low lip,  and supraglottic  larynx are known to metastasize 
bilaterally.
Anterior compartment neck dissection
This operation involves excision of the level VI lymph nodes. The 
procedure is indicated for the treatment of cancers of the thyroid gland, 
hypopharynx, cervical trachea, cervical esophagus, and subglottic larynx. 
The  boundaries  of  the  dissection  are  the  hyoid  hone  superiorly,  the 
suprasternal  notch  inferiorly,  and  the  carotid  sheaths  on  either  side. 
Hyopoparathyroidism may be a disabling complication if care is not taken 
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to  identify  and  preserve  the  parathyroid  glands,  and  injury  to  the 
parathyroid  blood  supply  is  a  risk  with  this  procedure.  Excising  and 
reimplanting the glands into the sternomastoid or pectoralis major muscles 
may be necessary. Alternatively, the dissection may be limited to one side 
if the lesion is not close to the midline, particularly if radiation therapy can 
be administered postoperatively.
Posterolateral neck dissection
Posterolateral neck dissection was initially described by Rochin in 
1962  and  later  modified  and  popularized  by  Geopfert  et  al  for  use  in 
patients with cutaneous malignancies of the scalp and postauricular and 
suboccipital  regions.  Unlike all  other  neck  dissections,  this  operation  is 
performed with the patient in the lateral decubitus position and consists of 
an en bloc removal of the lymph nodes in the suboccipital, postauricular, 
and upper, middle and lower jugular nodes, along with posterior triangle 
nodes  situated  superior  to  the  accessory  nerve.  Although  the  original 
description included sacrifice of the accessory nerve, internal jugular vein, 
and a portion of the trapezius muscle, Diaz et al from the MD Anderson 
Cancer  centre  showed  in  1996  that  preserving  these  non  lymphatic 
structures dies not increase the failure rate of this operation.
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Extended neck dissection
In  cases  of  advanced  neck  disease,  certain  lymphatic  or  non 
lymphatic  structures,  not  routinely  included  in  the  aforementioned  neck 
dissections,  may have to be removed.  Extended neck dissection is  the 
term used to describe these procedures. Retropharygeal lymph nodes, the 
hypoglossal nerve, portions of the prevertebral musculature, or the carotid 
artery are some of the structures that may occasionally have to be excised 
in order to obtain negative margins.
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MATERIALS AND METHODS
                 During a period of 29 months from august 2004 to february 
2006 datas were collected from 156 patients who were admitted to the 
surgical units of coimbatore medical college hospital with a diagnosis of 
cervical  lymphadenopathy.  Children  below  12  years  of  age  were  not 
included. All patients with known primaries were excluded from the study. 
Likewise  patients  with  lymphatic  malignancies  were  excluded.  Patients 
with infective pathology and non specific lymphadenitis were also excluded 
from the study. A total of 85 patients were finally included in the study. 
The workup for all the patients on admission was a follows:
History
A  detailed  history  was  obtained  from  all  patients,  attention  was 
focused on onset of swelling, duration of swelling ,rate of growth of the 
swelling  ,associated  pain,  pressure  and  obstructive  symptoms  like 
dizziness  (carotid  tree  involvement),shooting  pain  over  arm  (brachial 
plexus involvement), difficulty in breathing ,difficulty in swallowing, change 
in voice were elicited. History of otalgia, aural fullness, nasal congestion 
and  epistaxis  were  also  obtained.  Social  history  including  occupational 
hazards like exposure to ultraviolet light, industrial chemicals and metals 
were obtained. Information concerning alcohol consumption and tobacco 
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product usage were obtained. History of any irradiation to the head and 
neck in the past and past treatment of other head and neck carcinoma 
were elicited. Any associated illness were also noted.
Physical examination
The lymph node was taken significant  if  the size was more than 
1cm, spherical rather than ovoid in shape, hard in consistency.
          Note was made of the side and the triangle of the neck involved, the 
total  number of  palpable nodes,  the groups involved,  size,  consistency, 
presence  of  tenderness,  fixity  to  skin  as  well  as  deeper  structures, 
presence of any contralateral nodes and the N stage of the nodes.
          Nodes deep to the sternocleidomastoid were included in anterior 
cervical  triangle  as  the  classical  description  of  the  cervical  triangle 
excludes the nodes deep to the sternomastoid muscles from either of the 
two triangles. Midline nodes were considered as homolateral nodes. In all 
instances the clinical impression of the first observer was confirmed by at 
least one another observer.
          The physical examination was then focused on the head and neck, 
beginning with inspection and palpation of the skin. The scalp and external 
ears  were  inspected  in  detail.  All  zones  of  the  neck  were  palpated 
thoroughly in an effort to find additional lymphadenopathy or masses. The 
nasal  vestibule,  oral  cavity  and  oropharynx  were  thoroughly  inspected. 
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Because  submucosal  lesions  are  not  typically  evident  with  visual 
inspection, manual palpation of the oral cavity and the oropharynx were 
done.  Special  attention  was  paid  to  the  base  of  the  tongue  during 
palpation.  Special  focus  was  given  for  any  thyroid  swelling,  breast, 
respiratory system, abdomen, and genitalia were examined.
Chest  radiograph  was  done  for  all  patients.  For  patients  with 
suspicious lesions on chest radiograph, CT scan of the chest was done. 
Bronchoscopy was done for all patients
          Indirect laryngoscopy was done for all patients particularly looking 
for any growth or mucosal abnormalities in nasopharynx, oropharynx and 
larynx.
          Upper  gastrointestinal  endoscopy was  done  for  all  patients. 
Ultrasound abdomen was done for all patients.
          FNAC was done from the nodes. The histopathological report was 
expressed in three grades –Well  differentiated, moderately differentiated 
and  poorly  differentiated  carcinoma,  adenocarcinoma  and  papillary 
carcinoma thyroid.
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RESULTS OF THE STUDY
1. AGE DISTRIBUTION
      Incidence of age in nodal metastasis of neck with unknown primary
                                              Table - 1
Age in years No of cases out of 85 Percentage %
10-20 1 1
20-30 4 5
30-40 9 11
40-50 15 17
50-60 28 33
60-70 16 19
70-80 8 9
> 80 4 5
The overall age incidence for patients with head neck secondaries 
with unknown primary was in the range of 19-84 years with a mean of 52 
years.  Most  cases  presented  around  30-80years.  Among  the  5  cases 
presented below 30years 3 cases had papillary carcinoma thyroid
2. SEX DISTRIBUTION OF THE NODES
                            Sex distribution of the nodes
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                                               TABLE - 2
sex No of cases out of 85 Percentage%
Male 70 82
Female 15 18
               Out of the 85 patients with neck secondaries with unknown 
primary 70 (82%) patients were male, 15(18%) patients were female.
The following were the histopathological distribution among males 
and females;
                                             TABLE - 3                       
Histolopathology males Females
Poorly diff carcinoma 47 9
Mod diff carcinoma 2 1
Well diff carcinoma 14 1
Adenocarcinoma 2 1
Papillary ca thyroid 5 3
      
3. TOPOGRAGHICAL DISTRIBUTION OF NODAL METASTASES
                  
                      Analysis of topographical distribution of cervical node 
metastasis from various sites revealed the following patterns.
                                                           
                     46 patients (54.2%) presented with more than one group of 
nodes. Of these most of them were in the level II and level III.
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                     23 patients (27%) patients presented with bilateral nodes. 
Most of these patients had nodes in level II, level III and level IV. 
              
                   39 patients (45.8%) presented with only single group of nodes. 
The following pattern was noted in these patients.
                  
                   Out of the 39 patients who had a single group of nodes 74% 
had the nodes in level II and level III. 
                                 
                                         
Topographical distribution of nodes
TABLE - 4
   Lymph node levels No of patients out of 
39
Percentage
Level I 0 0
Level II 13 33.3
Level III 16 41
Level IV 6 15.3
Level V 4 10.2
Level VI 0 0
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Of the 39 patients  who presented with single node only,  most of 
them were in level II, III and level IV.
          No patients presented with level I  and level VI nodes with an 
unknown primary.
                              
                                  
                                                         
4.SIDE OF DISTRIBUTION OF THE NODES
                
                                                       TABLE - 5
                                          Side distribution of nodes
Side of the nodes No of patients out of 85 Percentage
Left 33 39
Right 52 61
              Of the 85 patients most of them(52 patients-61%)  presented with 
right sided nodes.33 patients(39%)  presented with left sided nodes
              
              The following are the histopathological distribution of nodes 
TABLE - 6
Histopatholgy Right Left
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Poorly diff carcinoma 36 20
Mod diff carcinoma 3 -
Well diff carcinoma 9 6
Adenocarcinoma 2 1
Papillary ca thyroid 2 6
5.HISTOPATHOLOGICAL ANALYSIS OF THE NODAL METASTASIS
                                
              Out of the 85 patients included in the study 56 patients(66%) had 
poorly  differentiated  carcinomatous  deposit  .15  patients  (18%)  had 
metastatic deposit from squamous cell carcinoma.
The histopathological analyses are presented in the following 
                                                 TABLE - 7
                             
Histology No of patients Percentage
Poorly differentiated metastatic carcinoma 56 66
Moderately differentiated metastatic 
carcinoma
3 3.5
Metastatic deposit from squamous cell 
carcinoma
15 18
Metastatic deposit from adenocarcinoma 3 3.5
Metastatic deposit of papillary carcinoma 
of thyroid
8 9
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TREATMENT
All  patients  with  operable  nodes  were  treated  with  radical  neck 
dissection. Those patients with extracapsular spread and multiple nodes 
were  given  radiotherapy and chemotherapy.  For  patients  with  operable 
bilateral nodes bilateral radical neck dissection was done in intervals.
For patients with inoperable masses chemoradiation was given.    
Combination chemotherapy with cisplatin (Days 1- 2) and 5-FU( for 
Days 1- 5) was regimen given for all the patients. 
Radiotherapy was given for 33 fractions of 300cGY per day for 5 
days/week. A total  dose of  6600 cGy was given. Palliative radiotherapy 
was given for advanced disease with 10 fractions of 200cGY per day. A 
total of 2000 cGY was given. 
For  patients  with  papillary  carcinoma  thyroid,  total  thyroidectomy 
with central neck dissection was done with radical neck dissection on the 
side of the lesion.                                     
During  the  29  months  study  no  subsequent  primary  site  was 
identified in all the patients.
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 DISCUSSION
Squamous cell carcinoma of the head and neck is the most common 
malignancy  in  India.  Treating  a  patient  with  malignant  cervical 
lymphadenopathy  poses  a  challenge  to  the  clinician  in  finding  out  the 
primary site.
• The incidence of malignant cervical lymphadenopathy in our studty 
was  2  % of all cancers. 
• The male to female ratio is 4:1 in our study, which matches with the 
world average44. The higher incidence in the males could be due to 
increased exposure to tobacco products and occupational hazards 
than females.
• The mean age in our study was 49 years for all types of malignant 
cervical lymphadenopathy with unknown primary, which is a decade 
earlier  than  western  average44.  80%  of  the  patients  presented 
between 30- 70 years. Highest incidence was seen between 50 – 60 
years.
• 66% of the patients had poorly differentiated carcinoma and 18% of 
the patients had well differentiated squamous cell carcinoma. This is 
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in contrast to the western literature where squamous cell carcinoma 
accounts  for  30%  -50%  and  poorly  differentiated  carcinoma 
accounts for 25%. This could imply that more aggressive cancers 
are seen in our part  of  the world.   This could be due to variable 
disease process or the various pathogenic factors playing a part.
• 27% of the patients presented with bilateral nodes, which means the 
most probable site of primary could be in the midline structures like 
base of tongue, nasopharynx and supraglottis.
• In our study we also noted a higher incidence on the right side(61%), 
when compared to the left side(39%). Are they due to keeping the 
tobacco products more commonly on the right is to be evaluated by 
further studies. 
• Out  of  8  patients  (9%)  of  papillary  carcinoma  thyroid  5  patients 
(62.5%) were male and 6 patients (75%) presented on the left side. 
• Of the 85 patients only 2 patients were from Christian community. 
The rest of them were from the Hindu community. This difference 
could be due to population ratio or social habits that are common in 
some communities. Is this a significant finding has to be evaluated 
by further studies.
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CONCLUSION
The  unknown  primary  tumour  presents  several  clinical  dilemmas 
including how to find the primary site and, if  the site is never found, to 
direct treatment.
              
The incidence of patients with an unknown primary site is low overall 
because  of  the  effectiveness  of  clinical  examination  coupled  with  pan 
endoscopy  and  directed  biopsies.  Radiograghic  technology  including 
CT/MRI, PET scan, and more recently,PET-CT may be of value in some 
cases.  As  these  diagnostic  methods  become  more  refined  there  may 
eventually be no patients  with  an unknown primary tumour.  Of  course, 
once the primary site is identified, treatment of this patients can become 
much  more  specifically  directed.  We  hope  that  in  future  the  unknown 
primary site will no longer be a featured entry.
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